13D Filing: RA Capital Management and Kalvista Pharmaceuticals Inc. (KALV)

Page 3 of 5 – SEC Filing

1

Names of Reporting Persons.

 

Peter Kolchinsky

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6

Citizenship or Place of Organization.
   United States

Number

of Shares

Beneficially

Owned by

Each Reporting

Person With

7

Sole Voting Power      0
shares

8

Shared Voting Power
1,441,070 shares

9

Sole Dispositive Power
0 shares

10

Shared
Dispositive Power      1,441,070 shares

11

Aggregate Amount Beneficially Owned by Each Reporting Person

1,441,070
shares

12 Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount in Row (11)

14.8%2

14

Type of Reporting Person (See Instructions)

HC, IN

2 The reporting person
is the beneficial owner of 1,441,070 shares of the Issuer’s Common Stock which constitute approximately 14.8% of the class
outstanding. The percentage calculation assumes that there are currently 9,713,042 outstanding shares of Common Stock of the Issuer,
based on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission (“SEC”) on September 14,
2017.

Follow Kalvista Pharmaceuticals Inc. (NASDAQ:KALV)